Literature DB >> 6250267

Bladder cancer following administration of cyclophosphamide.

C Durkee, R Benson.   

Abstract

The relationship between cyclophosphamide and hemorrhagic cystitis is well documented; its role in inducing bladder cancer is less clear. To date, 18 cases of cyclophosphamide-associated bladder tumors have been reported. We present 3 additional cases of transitional cell bladder cancer, all preceded by hemorrhagic cystitis. Data implicating cyclophosphamide as a direct carcinogen as well as an immunosuppressive agent allowing bladder tumor development in the compromised host are discussed. While no direct relationship has been established, we suggest patients receiving this drug are at risk for developing bladder cancer, more likely transitional cell rather than squamous cell as has been reported previously.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6250267     DOI: 10.1016/0090-4295(80)90068-0

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  4 in total

1.  Osteosarcoma after chemotherapy for neuroblastoma.

Authors:  V M Kriss; C B Stelling
Journal:  Skeletal Radiol       Date:  1995-11       Impact factor: 2.199

2.  Cyclophosphamide is contraindicated in patients with a history of transitional cell carcinoma.

Authors:  Bjoern G Volkmer; Evelyn M Seidl-Schlick; Dietmar Bach; Imre Romics; Klaus Kleinschmidt
Journal:  Clin Rheumatol       Date:  2004-12-01       Impact factor: 2.980

3.  Bladder carcinoma following cyclophosphamide therapy. A case report.

Authors:  H Kiesswetter; N Baloch; J Flamm
Journal:  Int Urol Nephrol       Date:  1985       Impact factor: 2.370

Review 4.  Comparative activity of ifosfamide and cyclophosphamide.

Authors:  W Brade; S Seeber; K Herdrich
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.